-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Acumen Pharmaceuticals (NASDAQ:ABOS) & Achilles Therapeutics (NASDAQ:ACHL) Head-To-Head Analysis
Acumen Pharmaceuticals (NASDAQ:ABOS) & Achilles Therapeutics (NASDAQ:ACHL) Head-To-Head Analysis
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Institutional and Insider Ownership
67.9% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are owned by institutional investors. 4.7% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Get Acumen Pharmaceuticals alerts:Analyst Ratings
This is a breakdown of recent ratings and price targets for Acumen Pharmaceuticals and Achilles Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
| Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Risk and Volatility
Acumen Pharmaceuticals has a beta of -1.92, suggesting that its share price is 292% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Profitability
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -18.16% | -17.72% |
| Achilles Therapeutics | N/A | -26.40% | -23.89% |
Valuation and Earnings
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | $1.44 million | 161.17 | -$100.61 million | N/A | N/A |
| Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.67 |
Achilles Therapeutics has lower revenue, but higher earnings than Acumen Pharmaceuticals.
About Acumen Pharmaceuticals
(Get Rating)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
About Achilles Therapeutics
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Acumen PharmPharmticals(纳斯达克：ABOS-GET评级)和阿喀琉斯治疗(纳斯达克：ACHL-GET评级)都是小盘医疗公司，但哪只股票更好？我们将根据这两家公司的机构所有权、分析师建议、风险、盈利能力、估值、收益和股息的实力进行比较。
Institutional and Insider Ownership
机构和内部人持股
67.9% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are owned by institutional investors. 4.7% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Acumen PharmPharmticals 67.9%的股份由机构投资者持有。相比之下，阿喀琉斯治疗公司69.7%的股份由机构投资者持有。Acumen PharmPharmticals 4.7%的股份由公司内部人士持有。相比之下，阿喀琉斯治疗公司5.4%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、大型基金经理和对冲基金相信，从长期来看，一只股票的表现将好于大盘。
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and price targets for Acumen Pharmaceuticals and Achilles Therapeutics, as reported by MarketBeat.com.
据MarketBeat.com报道，这是Acumen制药公司和阿喀琉斯治疗公司最近的评级和目标价细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
| Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Acumen制药公司 | 0 | 0 | 4 | 0 | 3.00 |
| 阿喀琉斯治疗学 | 0 | 1 | 2 | 0 | 2.67 |
Risk and Volatility
风险和波动性
Acumen Pharmaceuticals has a beta of -1.92, suggesting that its share price is 292% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Acumen PharmPharmticals的贝塔系数为-1.92，这表明其股价的波动性比标准普尔500指数低292%。相比之下，阿喀琉斯治疗公司的贝塔系数为0.6，这表明其股价的波动性比标准普尔500指数低40%。
Profitability
盈利能力
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' net margins, return on equity and return on assets.
此表比较了Acumen制药公司和阿喀琉斯治疗公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -18.16% | -17.72% |
| Achilles Therapeutics | N/A | -26.40% | -23.89% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Acumen制药公司 | 不适用 | -18.16% | -17.72% |
| 阿喀琉斯治疗学 | 不适用 | -26.40% | -23.89% |
Valuation and Earnings
估值和收益
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.
该表比较了Acumen制药公司和阿喀琉斯治疗公司的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | $1.44 million | 161.17 | -$100.61 million | N/A | N/A |
| Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.67 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Acumen制药公司 | 144万美元 | 161.17 | -1.0061亿美元 | 不适用 | 不适用 |
| 阿喀琉斯治疗学 | 不适用 | 不适用 | -6,110万美元 | ($1.66) | -0.67 |
Achilles Therapeutics has lower revenue, but higher earnings than Acumen Pharmaceuticals.
阿喀琉斯治疗公司的收入低于Acumen制药公司，但收益高于Acumen制药公司。
About Acumen Pharmaceuticals
关于Acumen制药公司
(Get Rating)
(获取评级)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen制药公司是一家临床阶段的生物制药公司，发现和开发治疗阿尔茨海默病的疗法。该公司专注于开发一种靶向免疫治疗候选药物ACU193，这是一种人源化单抗，正处于I期临床阶段，用于靶向可溶性淀粉样β寡聚体。Acumen制药公司成立于1996年，总部设在弗吉尼亚州夏洛茨维尔。
About Achilles Therapeutics
阿喀琉斯疗法公司简介
(Get Rating)
(获取评级)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
阿喀琉斯治疗公司是一家临床阶段免疫肿瘤学生物制药公司，开发用于治疗各种实体肿瘤的精密T细胞疗法。该公司的主要候选产品包括用于治疗晚期非小细胞肺癌的处于I/IIa阶段临床试验的ChIron和用于治疗转移性或复发黑色素瘤的处于I/IIa阶段临床试验的候选产品Thetis。它还在开发用于治疗头颈部鳞状细胞癌、肾细胞癌、三阴性乳腺癌和膀胱癌的产品。该公司前身为Achilles TX Limited，2021年2月更名为Achilles Treateutics Plc。该公司成立于2016年，总部设在英国伦敦。
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Acumen PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acumen制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧